<p>Researchers at Trinity College Dublin, in collaboration with Breye Therapeutics, have found that an oral medication ("Danegaptide") can protect against vision-threatening damage in nonproliferative diabetic retinopathy (NPDR), a leading cause of blindness in working-age adults.</p>